Full Press Release Details
Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin
demonstrated the safety and efficacy of the ORMD 0801- oral insulin capsule
Israel - August 6, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB;
developer of oral delivery systems, announced today successful results from
clinical trial of its oral insulin capsule, ORMD 0801. The trial demonstrated
that the product had a good safety profile and was well tolerated and effective
in lowering blood glucose levels in patients with type 2 diabetes.
was conducted at Hadassah University Medical Center in Jerusalem and was a
continuation of the successful Phase 1B trials that Oramed completed earlier
trial was the first to expose patients with type 2 diabetes to ORMD 0801 and
primary goals were to assess the safety, tolerability and pharmcodynamic effects
was well tolerated by all patients and had a good safety profile; no serious
adverse events were encountered throughout the study. In 6 of the 9 subjects
analyzed, statistically significant reductions in glucose as well as C-peptide
pleased with the results from the Phase 2A trial as they showed that ORMD 0801
was effective and there were no safety issues," said Oramed's Chief Scientist,
Dr. Miriam Kidron. "We look forward to our next phase of testing and taking the
next steps towards making an oral insulin capsule a reality for millions of
diabetics around the world."
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in Jerusalem.
more information, please visit www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Finn Israel for Oramed